Interview thoughts9 Jun 2022 17:52
I've just watched Andrew Newland's interview with Sarah Lowther, and as a long term shareholder of AGL just wanted to share some thoughts. Andrew has given many highly impressive presentations and interviews over the years, in which he always sounds very impassioned, committed and professional. This interview was no different. What really came across in this interview however was his complete honesty in stating that altruism and wanting to make a difference to cancer patients worldwide is his motivating force in wanting to commercialize Parsortix, not making money. He also made it clear he would like long-term investors onboard rather than day-traders and hedge funds. Whilst I recognise that this message will not sit well with many AIM investors, many of whom are out to make a quick buck, and have probably jumped on the post-FDA clearance bandwagon, those of us who have followed the Angle and Parsortix story since its inception will realise that his message is actually two-fold: that Parsortix can and will revolutionize cancer care but at the same time presents an enormous unlimited commercial opportunity which will reward investors long-term. Andrew has stated that short term revenues with margins of over 75% will initially come from pharma services, followed progressively more revenue generation over the years from further collaborations with companies in the liquid biopsy space. The recent sell off post FDA clearance is over done in my opinion and reflects the short-term outlook of the AIM investor mentality rather than the longer term capital builder type investor.
Sign In
Follow the stocks
